Please login to the form below

Not currently logged in
Email:
Password:

BioMarin’s chief commercial officer joins True North’s board

Jeff Ajer brings over 20 years of industry experience to the biotech

True North Therapeutics Jeff AjerCalifornia, US-based biotech True North Therapeutics has appointed Jeff Ajer to its board of directors as an independent director.

Ajer currently serves as executive vice president and chief commercial officer of BioMarin, and was previously the firm's vice president of commercial operations for the Americas.

He first joined BioMarin in 2005 from Genzyme, where he was vice president of global transplant operations, and prior to this held a series of sales, marketing and operations positions at SangStat Medical Corporation and ICN Pharmaceuticals.

Nancy Stagliano, chief executive officer of True North Therapeutics, said: “We are delighted that Jeff has joined our board.

“We believe his extensive commercial experience with products for rare diseases, which includes over 11 years at BioMarin where he built the company's commercial infrastructure and led successful drug launches, will be invaluable as we continue to build a pipeline of innovative medicines designed to treat Complement-mediated rare diseases.”

20th February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...